CHART 1

<b>Setting:</b> Tuberculosis remains a global challenge, requiring diagnostic innovations, especially for tuberculosis infection cases. <b>Objective:</b> This study aimed to analyze patent registers related to tuberculosis diagnosis in a Brazilian database, promoting reflections on knowledge translation into clinical practice. <b>Design:</b> This electronic documentary research was carried out in March 2025 in the National Institute of Industrial Property database. Data were assessed descriptively and analyzed by using absolute and relative frequencies. <b>Results:</b> Of the 62 patents found, 71% were published by 2015, with an average time of 1,274 days between filing and publication. Half of filers were companies or large corporations. Most patents refer to pharmaceutical compositions also intended for treatment and vaccines. Only six complete kits aimed at detecting tuberculosis disease and tuberculosis infection, based on adenosine deaminase, sputum culture, MPB64 protein, fusion proteins or synthetic peptide antigen. Some include assays for strains resistant to isoniazid and rifampicin. <b>Conclusion:</b> The scarcity of registered innovative products reveals gaps in the early diagnosis of tuberculosis, especially in tuberculosis infection. Investments in biotechnology and artificial intelligence may represent promising strategies to strengthen the fight against tuberculosis.